Source: Eur Respir J 2002; 20: 66S-77S
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Loddenkemper R., Sagebiel D., Brendel A.. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20: 66S-77S

Member's Comments

No comment yet.

Related content which might interest you: Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Source: Eur Respir J 2013; 41: 1393-1400 Year: 2013 Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 The problem of multi-drug resistant (MDR)-TB Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016